SLXN

NASDAQ · Biotechnology

Silexion Therapeutics Corp

Penny Stocks Biotech Stocks Healthcare Stocks

$2.57

-0.18 (-6.55%)

As of Jun 29, 10:45 PM ET ·

SLXN News2 articles

Silexion Rockets 97% on Cancer Trial News, Nasdaq Compliance and Cash Concerns Remain

Silexion Therapeutics shares surged 97% on Wednesday following Israeli approval for a Phase 2/3 trial of its pancreatic cancer drug SIL204, but the company still grapples with cash burn, dilution risks, and Nasdaq compliance.

Silexion Advances Pancreatic Cancer Trial Amid Cash Concerns

Silexion Therapeutics progresses its SIL204 pancreatic cancer drug into clinical trials, but a shrinking cash position and recent stock decline highlight funding challenges.